Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Our pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). Acer’s product candidates are believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development.
Ticker:
ACER
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
Emetine for COVID-19; ACER-001 for UCDs
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
